Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018Jonathan M. Loree, Kanwal Raghav, Seerat Anand et al.|JAMA Oncology|2019Cited by 568
Clinical and molecular characterization of early‐onset colorectal cancerAlexandra N. Willauer, Jonathan M. Loree, Van K. Morris et al.|Cancer|2019Cited by 361
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular SubtypesJonathan M. Loree, Scott Kopetz, Allan Andresson Lima Pereira et al.|Clinical Cancer Research|2017Cited by 318
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving PracticesMidhun Malla, Aparna R. Parikh, Jonathan M. Loree et al.|Journal of Clinical Oncology|2022Cited by 276
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeChristine M. Parseghian, Scott Kopetz, Jonathan M. Loree et al.|Annals of Oncology|2018Cited by 239